Hsbc Holdings PLC Has $70.05 Million Stock Position in United Therapeutics Corporation $UTHR

Hsbc Holdings PLC lowered its position in United Therapeutics Corporation (NASDAQ:UTHR) by 8.1% during the 4th quarter, Holdings Channel reports. The fund owned 143,624 shares of the biotechnology company’s stock after selling 12,743 shares during the period. Hsbc Holdings PLC’s holdings in United Therapeutics were worth $70,053,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Geneos Wealth Management Inc. raised its position in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC acquired a new stake in United Therapeutics in the 2nd quarter valued at $277,000. Cerity Partners LLC grew its position in United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia increased its stake in United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.3%

NASDAQ UTHR opened at $538.30 on Tuesday. The firm has a market capitalization of $22.85 billion, a P/E ratio of 19.87, a PEG ratio of 1.75 and a beta of 0.57. The business has a fifty day simple moving average of $563.74 and a 200 day simple moving average of $524.17. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.63 earnings per share. As a group, sell-side analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on UTHR shares. HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Finally, Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $552.40, for a total transaction of $5,247,800.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,379,381.20. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $540.15, for a total transaction of $5,401,500.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,195,871.40. This trade represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 634,968 shares of company stock worth $359,124,602 over the last quarter. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.